On 18 April 2026, President Donald Trump issued an executive order that aims to accelerate the development and review of psychedelic drugs as treatments for serious mental health conditions such as PTSD, depression, and addiction. This order directs federal agencies like the Food and Drug Administration (FDA) and the Department of Health and Human Services to fast-track regulatory pathways for qualifying breakthrough therapies. These efforts focus on expanding research and review processes for substances beyond currently used ketamine-assisted treatments, including psilocybin, methylone, and ibogaine.
In a collaborative initiative, Leslie Elliott-Boyce of Radical Centre and CTA co-directors Michael Olan and Jaco van Zyl explore the politics and ethics of psychedelics with Karen King. Fellow CTA members will be familiar with Karen, who is an experienced psychotherapist, clinical supervisor and trainer, specialising in ketamine-assisted psychotherapy and psychedelic integration.
In this discussion, the interlocutors explore the current state of psychedelic-assisted psychotherapy and how it is regulated in the United States at both federal and state levels. They consider what this executive order is aiming to achieve and the implications it may have for this specialised area of psychotherapy. They examine concerns about the influence of Critical Social Justice perspectives on the field and the potential corrupting impact of such frameworks on its development. Karen explains what psychedelic-assisted therapy involves, its potential benefits, and who might typically seek this form of treatment. The discussion also considers how this approach to therapy may be compatible with a range of worldviews that include an appreciation for the mystical, including monotheistic religious traditions.






Leave a Reply